DAMIANO Graziani

Dr. DAMIANO Graziani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AFAndrea Fuschi
Andrea Fuschi
MSmanfredi bruno sequi
manfredi bruno sequi
YSYazan Al Salhi
Yazan Al Salhi
PSPaolo Pietro Suraci
Paolo Pietro Suraci
FVFabio Maria Valenzi
Fabio Maria Valenzi
Antonio Luigi PastoreAntonio Luigi Pastore
Antonio Luigi Pastore
Background: Cold dissection (CD) during nerve-sparing robot-assisted radical prostatectomy (nsRARP) in patients with prostate cancer has been proposed to improve functional outcomes by reducing the thermal damage to neurovascular bundles (NVBs). This study compares the impact of CD versus thermal dissection (TD) on postoperative early continence and erectile function recovery. Methods: A prospective comparative analysis was conducted on patients undergoing nsRARP, comparing CD and TD techniques. Continence was assessed at 15, 30, and 90 days, while erectile function was evaluated at 30, 90, and 180 days using IIEF-5 scores. Logistic and linear regression analyses were performed to identify predictors of functional recovery. Results: CD significantly improved early continence at 15 and 30 days (p < 0.05), although the difference diminished by 90 days. Erectile function recovery was consistently higher in the CD group at all time points (p < 0.01). Age negatively impacted continence and erectile function recovery, while preoperative IIEF-5 scores were strong predictors of erectile function. Prostate volume, BMI, and metabolic syndrome showed no significant influence on outcomes. Conclusions: CD enhances early continence and erectile function recovery following nsRARP by preserving NVBs and minimizing thermal damage. This technique offers a valuable approach to improving patient functional outcomes. Further studies are required to validate its long-term benefits.

2 May 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
AFAndrea Fuschi
Andrea Fuschi
YSYazan Al Salhi
Yazan Al Salhi
Antonio Luigi PastoreAntonio Luigi Pastore
Antonio Luigi Pastore
MSmanfredi bruno sequi
manfredi bruno sequi
CNCosimo De Nunzio
Cosimo De Nunzio
ACAntonio Carbone
Antonio Carbone
Background: Minimally invasive surgery has improved patient outcomes but raises environmental concerns due to carbon emissions from disposable instruments, energy consumption, and hospital resource use. This study evaluates the carbon footprint of robot-assisted and laparoscopic nephrectomies. Methods: A multicenter prospective study analyzed 162 patients undergoing robot-assisted or laparoscopic partial (RAPN, LPN) and radical nephrectomy (RARN, LRN). Life cycle assessment (LCA) quantified CO2 emissions from instrument use, sterilization, and energy consumption. Results: Robot-assisted procedures had lower CO2 emissions than laparoscopic approaches. Emissions from instrument disposal were 9.04 kg in RAPN vs. 12.14 kg in LPN (p = 0.02) and 8.74 kg in RARN vs. 11.45 kg in LRN (p = 0.03). Despite higher intraoperative energy use, robot-assisted surgery produced 3–4 kg less CO2 per procedure due to reusable instruments and shorter hospitalization. Conclusions: Robot-assisted nephrectomy reduces environmental impact by minimizing waste and hospital stays. Efforts should focus on reusable instruments, energy efficiency, and sustainability initiatives to mitigate surgical carbon footprints while ensuring high-quality care.

12 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PSPaolo Pietro Suraci
Paolo Pietro Suraci
MSmanfredi bruno sequi
manfredi bruno sequi
FVFabio Maria Valenzi
Fabio Maria Valenzi
YSYazan Al Salhi
Yazan Al Salhi
OROnofrio Antonio Rera
Onofrio Antonio Rera
AFAndrea Fuschi
Andrea Fuschi
Introduction: Post-prostatectomy incontinence (PPI) remains a major functional concern after robot-assisted radical prostatectomy (RARP). Posterior musculofascial reconstruction (PMFR) has been shown to facilitate early urinary continence (EUC), but variations in technique may further improve outcomes. We evaluated whether a modified vesicourethral anastomosis (VUA) incorporating simultaneous PMFR with a single barbed suture [pontine VUA (P-VUA)] may facilitate continence recovery compared with the standard Van Velthoven anastomosis (ST-VUA). Materials and Methods: This prospective study included patients undergoing RARP between January 2021 and December 2023. Allocation was based on surgeon preference. UC was defined as the use of no pads or one dry safety pad per day and was assessed at 10, 30, 90, 180, and 365 days after catheter removal. Multivariable logistic regression was performed to evaluate factors associated with 30-day continence. Time to continence was additionally analyzed using Kaplan–Meier methods. Results: This prospective comparative study included 157 patients undergoing robot-assisted radical prostatectomy (RARP) between January 2021 and December 2023 (76 ST-VUA, 81 P-VUA). Baseline and pathological characteristics were comparable between groups. Catheterization time was significantly shorter in the P-VUA group (5.0 ± 1.1 vs. 6.7 ± 1.4 days, p < 0.001). Continence rates were higher in the P-VUA group at 10 days (72.8% vs. 55.3%, p = 0.03), 30 days (84.0% vs. 68.4%, p = 0.035), 90 days (92.6% vs. 76.3%, p = 0.007), 180 days (93.8% vs. 82.9%, p = 0.044), and 365 days (97.5% vs. 86.8%, p = 0.015). Kaplan–Meier analysis demonstrated a shorter time to continence in Group P (log-rank p = 0.0037). In multivariable analysis, P-VUA was independently associated with higher odds of 30-day continence (OR 6.38, 95% CI 2.08–19.63, p = 0.001). Conclusions: The study suggests that the P-VUA technique was associated with faster recovery of urinary continence compared with ST-VUA in this prospective, non-randomized cohort. These findings support the hypothesis that integrating anatomical reconstruction principles into the anastomotic step may enhance functional outcomes after RARP. However, the results should be interpreted with caution, given the study design and sample size, and require confirmation in larger, preferably randomized studies.

26 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PSPaolo Pietro Suraci
Paolo Pietro Suraci
AFAndrea Fuschi
Andrea Fuschi
MSmanfredi bruno sequi
manfredi bruno sequi
FVFabio Maria Valenzi
Fabio Maria Valenzi
AAAlice Antonioni
Alice Antonioni
Antonio Luigi PastoreAntonio Luigi Pastore
Antonio Luigi Pastore
Background/Objectives: The optimal surgical approach for kidney stones (KS) measuring 15–20 mm remains debated. RIRS and mini-PCNL are both effective options, but they differ in invasiveness, resource use, and cost. This study aimed to compare perioperative outcomes and hospital costs of RIRS and mini-PCNL using a micro-costing approach. Methods: This retrospective study included patients with KS > 15 mm in diameter who were treated between January 2021 and December 2023 at the Department of Urology, Sapienza University of Rome-Polo Pontino. Clinical parameters, operative time (OT), length of stay (LoS), complications, and stone-free rate (SFR) were compared. Costs were estimated using a micro-costing method, including disposable materials, operating room (OR) time (3.9 EUR/min), imaging, and hospitalization (334 EUR/day). The total cost per treated and per SF patient was calculated for both techniques. Results: A total of 119 patients were analyzed: 62 underwent RIRS, and 57 underwent mini-PCNL. Mean OT was shorter for RIRS (87 vs. 113 min; p < 0.001), and LoS was longer for mini-PCNL (2.24 vs. 1.22 days; p = 0.008). Final SFR was higher for mini-PCNL (94.7% vs. 88.7%; p = 0.043). Complication rates were comparable, with most events classified as Clavien–Dindo I–II. Disposable materials represented the main cost driver (EUR 1097 for RIRS vs. EUR 806 for mini-PCNL). The total cost per treated patient was EUR 3689 for RIRS and EUR 3154 for mini-PCNL (p = 0.009). The cost per SF patient was EUR 4159 for RIRS and EUR 3331 for mini-PCNL (p = 0.007). Conclusions: Both RIRS and mini-PCNL are safe and effective for the management of KS ≥ 15 mm. Mini-PCNL achieves higher SFR and greater cost-efficiency than RIRS. These findings support the use of mini-PCNL as the preferred option in centers with adequate expertise and resources.

3 February 2025 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PSPaolo Pietro Suraci
Paolo Pietro Suraci
YSYazan Al Salhi
Yazan Al Salhi
GCGiuseppe Candita
Giuseppe Candita
AFAndrea Fuschi
Andrea Fuschi
SSSilvio Scalzo
Silvio Scalzo
Antonio Luigi PastoreAntonio Luigi Pastore
Antonio Luigi Pastore
Seminal vesicle neoplasms are extremely rare. Schwannoma is a benign tumor of the peripheral nerve sheath composed of Schwann cells. Most of these tumors are silent and become symptomatic with compression of adjacent organs and nerves. We present a case of a 65-year-old man with a history of predominant storage lower urinary tract symptoms. Prostate-specific antigen was within normal ranges, and imaging documented a nodular lesion in the prostate, one in the left seminal vesicle and another one adjacent to the right bladder wall. We successfully performed a prostate biopsy and a trans-urethral resection of the bladder to excise and typify the lesion. Histopathology investigation revealed the final diagnosis of schwannoma.

6 July 2025 in Medicina
Verified
Journal Article
Open access
PDF file
YSYazan Al Salhi
Yazan Al Salhi
DGDAMIANO Graziani
DAMIANO Graziani
AFAndrea Fuschi
Andrea Fuschi
FVFabio Maria Valenzi
Fabio Maria Valenzi
MSmanfredi bruno sequi
manfredi bruno sequi
Antonio Luigi PastoreAntonio Luigi Pastore
Antonio Luigi Pastore
Background and Objectives: While α1-blockers like silodosin are the mainstay for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), combination therapy with phytotherapeutics may provide enhanced symptom control. Xipag® is a novel formulation containing Graminex® G96 (pollen extract) and Teupol® 25P (teupolioside), offering anti-inflammatory and antiandrogenic effects. This study aimed to evaluate the efficacy of Xipag® versus hexanic extract of Serenoa repens (HESr), both in combination with silodosin, in patients with LUTS/BPH. Materials and Methods: We conducted a single-center, prospective, observational, comparative study involving male patients with moderate-to-severe LUTSs undergoing treatment with silodosin. Patients were allocated to receive either Xipag® or HESr in addition to silodosin, with follow-up every 3 months for 12 months. Primary outcomes included changes in symptom scores such as IPSS, QoL, and functional improvements such as peak urinary flow rate (Qmax). Multivariable regression analyses were used to assess predictors of the response. Results: Patients receiving Xipag® showed significantly greater improvements in Qmax at all follow-up points (p < 0.05), with earlier and more sustained benefits compared to the HESr group. QoL index scores and PSA levels were also significantly better in the Xipag® group starting from month six onward. IPSS scores improved in both groups but were significantly lower in the Xipag® group only at 12 months (p = 0.04). No differences in erectile function (IIEF-5) or adverse events were observed. Conclusions: Xipag® in combination with silodosin provides superior improvement in urinary flow, symptom-related QoL, and PSA reduction compared to HESr plus silodosin, with a favorable safety profile. These findings support the use of multi-target nutraceuticals like Xipag® as a valuable adjunct in the management of LUTS/BPH. Larger randomized trials are warranted to confirm these results and explore underlying mechanisms.